A new and innovative treatment for open wounds

PATHELEN® WoundPowder is a new microporous silica powder, that adsorbs wound exudate, reducing the healing time of chronic wounds and offers a cost-effective alternative to the current treatment options for wounds.

PATHELEN® is a pioneering European Class I Certified, U.S.FDA approved medical device without side effects and antimicrobial resistant safe.

PATHELEN® WoundPowder is an effective and powerful replacement for all other currently available antimicrobial wound treatment devices.

*PATHELEN® Woundpowder and PATHELEN® Hybrid are the same product. PATHELEN® is sold as PATHELEN® Woundpowder in Ghana & Nigeria only.

Chronic wounds include venous leg ulcers, diabetic ulcers and pressure ulcers. The cost of management is high and many are infected, requiring the use of antibiotics.
The mean cost of venous leg ulcers over 12 months = $10,000 per ulcer and the mean time to healing was 3 months & up to 30% of leg ulcers were either infected or at risk of infection.1
The mean cost of diabetic ulcers over 12 months = $10,200 per diabetic ulcer and up to 45% of ulcers were either infected or at risk of infection.2
The mean cost of pressure ulcers over 12 months = $11,480 per pressure ulcer and up to 53% were either infected or at risk of infection.3
1.Guest et al Int Wound J 2018;15(1): 29-37.
2. Guest et al Int Wound J 2018; 15(1): 43 –52.

3.Guest et al BMJ Open 2018; 8:e021769.


PATHELEN® WoundPowder is a powder which contains both hydrophilic and hydrophobic silicas in a highly porous structure. Through capillary action, these silicas act to irreversibly adsorb wound exudative material (including bacterial toxins) to the upper surface of the layers of the powder from where it effectively evaporates.


PATHELEN® WoundPowder thus “de-toxifies” and cleans the wound.


PATHELEN® WoundPowder is not antibacterial but withdraws water from a bacterial biofilm, disrupting its structure and allowing the host’s immune system to gain entry and destroy the microorganisms present.


Due to its mode of action, PATHELEN® WoundPowder is able to treat a WIDE range of acute and chronic wounds.


Infected burn wounds
Diabetic/ neuropathic ulcers
Exuding wounds
Wounds with resistant nuclei
Fungating, cancerous or malignant lesions and wounds with necrotic tissue
Post-operative wounds
Traumatic wounds
Elephantiasis open wounds
Any open wounds with a biofilm


Aerosil 300 Pharma

Aerosil R972 Pharma

Benzalkonium Chloride

By disrupting the wound’s biofilm, it allows entry of the body’s own immune cells, which destroy microorganisms within the biofilm, promoting the natural healing process and reducing the need for antibiotics.

PATHELEN® WoundPowder is an effective and powerful replacement for all other currently available antimicrobial wound treatment devices.

Clinical practice shows that the current, individual use of other antimicrobial agents in the treatment of purulo-inflammatory diseases and purulent wounds, does not always lead to the desired result. Additionally, misuse of antibiotics has contributed to the emergence of resistant (hospital) strains of pathogenic microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA), and become a serious challenge for modern medicine.


PATHELEN® WoundPowder can solve this problem, utilising new compositions based on highly dispersed silicas and which have enhanced absorptive, anti-inflammatory and wound-healing abilities for the treatment of a wide range of diseases caused by pathogenic microorganisms, in particular, purulent wounds. The intensity of the regeneration process and healing of infected ulcers and wounds depends largely on the speed with which they are cleared of pus and necrotic tissues. Applique sorption, a method of wound healing in which an absorbent in powder form is applied to the wound as a dressing, greatly accelerates this process. This absorption detoxification restores the integrity of the skin and mucous membranes by the removal of microbial cells, bacterial toxins and toxic metabolites of wound fluid and wound cavities in direct contact with the surface of PATHELEN®.


Another important therapeutic factor in the first phase of wound healing is dehydration, i.e. absorption of fluid from the wound cavity and perifocal tissues. Hydrophilic highly dispersed silica (HDS) can be used in the first phase of wound healing. Its detoxifying action is due to the absorption of pathogenic protein substances (up to 800 mg/g), including microbial enzymes, exo-and endotoxins (Lipopolysaccharides) and micro-organisms.

PATHELEN® contains a unique patented formula, which when shaken for 15-20 seconds, will grow visibly in density by more than 20 times, creating the advanced sorption property and filling the bottle content

How do I use PATHELEN®

The bottle of PATHELEN® should be shaken vigorously for about 15 seconds, at which point the powder becomes gel-like and should then be applied over the surface of the wound

How fast does it work?

PATHELEN® eliminates most bacterial and fungal wound infections within an average 8.5 days although the healing time will vary depending on the size of the wound.

Is there a restriction on how often it can be used?

No, PATHELEN® can be used daily until the appearance of granulation tissue. PATHELEN® has also shown to be safe if left on the wound for a longer period of time

Does PATHELEN® stick on the wound when the dressing is removed?

No, it doesn’t

Can PATHELEN® be used safely on children/babies and pregnant women?

Yes. There are no restrictions on who can use PATHELEN®.

Can PATHELEN® be administered without specialist training?

Yes, no specialist training is required to use PATHELEN® although it is advised that the assessment of a wound is undertaken by a health professional.

Medical Device Class I - EMA European Medicine Agency (CE) Swissmedic registered under CH-201805-0002

U.S. FDA Regulation Number 3017399130
Nigerian NAFDAC 03-6974
Ghana FDA FDA/D.19-3044

Reuters issued a study report on ’Surgery death rates in Africa is twice the global average’ in January 2018.

It showed about one in five surgery patients developed a complication Comparisons with international data for elective surgery showed that death rates from elective surgery were 1 percent in Africa compared with 0.5 percent for the global average.
January 2018
February 2018
March 2018
April 2018
May 2018
Title Event Happening
Title Event Happening
Title Event Happening
Title Event Happening
Title Event Happening

Explore other products


PATHELEN® Hybrid Vet

PATHELEN® Alkaline Vitality Complex

See the amazing results of PATHELEN® treatments in our Case Studies.


PATHELEN® Hybrid Vet

PATHELEN® Alkaline Vitality Complex